Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bortezomib, Bortezomib (Velcade®)
Velcade · 1 trial · 1 indication
The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by overall response rate (ORR) to therapy. ORR is the sum of patients with a Complete Response and Partial Response to therapy. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete REsponse (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by progression-free survival (PFS).
| Arm | Type | Description |
|---|---|---|
| Velcade plus Temsirolimus | EXPERIMENTAL | Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29) Treat for up to 6 cycles, cycles are 35 days long. |
| Name | Type | Description |
|---|---|---|
| Velcade | DRUG | Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22) |
| Temsirolimus | DRUG | Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29) |
Inclusion Criteria: * Relapsed or refractory B-cell non-Hodgkin lymphoma which includes: diffuse large B-cell lymphoma; primary mediastinal large B-cell lymphoma; follicular lymphoma (grade 1, 2 or 3); mantle cell lymphoma; small lymphocytic lymphoma; marginal zone lymphoma; lymphoplasmacytic lymph...
Velcade is a small molecule being studied for the treatment of Non-Hodgkins Lymphoma. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in patients with relapsed or refractory disease, meaning it is intended for cases where prior treatment has not been successful.
Velcade targets the proteasome, a cellular complex that degrades proteins. It belongs to the -zomib class of proteasome inhibitors. By inhibiting the proteasome, Velcade disrupts protein homeostasis in cancer cells, which can lead to cell death. This mechanism is being explored in the context of Non-Hodgkins Lymphoma.
Velcade is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research to evaluate Velcade's safety and efficacy in patients with Non-Hodgkins Lymphoma.
Velcade is in Phase 2 clinical development for Non-Hodgkins Lymphoma. It is an investigational drug, meaning it has not been approved by regulatory authorities for this indication. The Phase 2 trial has been completed, and the drug is not currently in active clinical trials for this condition.
Velcade has been studied in one completed Phase 2 clinical trial, identified as NCT01281917. This trial, titled "Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma," enrolled 40 participants in the United States. The study was uncontrolled and not blinded, and it included biomarker-selected patients.
Yes, Velcade is the same as Bortezomib. Bortezomib is the generic name for the drug, while Velcade is the brand name. The drug is also known as Bortezomib (Velcade®). In clinical trials and scientific literature, it may be referred to by either name.